ADUpdating your news feed...

NEWS EXPRESS is Nigeria’s leading online newspaper. Published by Africa’s international award-winning journalist, Mr. Isaac Umunna, NEWS EXPRESS is Nigeria’s first truly professional online daily newspaper. It is published from Lagos, Nigeria’s economic and media hub, and has a provision for occasional special print editions. Thanks to our vast network of sources and dedicated team of professional journalists and contributors spread across Nigeria and overseas, NEWS EXPRESS has become synonymous with newsbreaks and exclusive stories from around the world.

























Loading banners
Loading banners...


Bioresources CEO, Prof Maurice Iwu
The Federal Government is yet to show commitment on the treatment of Coronavirus as presented by the Bioresources Development Group (BDG) team of researchers, its Chief Executive Officer (CEO) of), Prof. Maurice Iwu, has said.
Iwu made this known during a Zoom conference organized by Elombah Communications in collaboration with Njenje Media Ltd, tagged ‘Covid-19 and the Proposed Vaccination Bill: Implications for Nigeria’.
The former INEC boss who led a team of researchers had presented a plant-based patented treatment for COVID-19 to the Minister of Science and Technology, Dr Ogbonnaya Onu.
But Iwu, while speaking at the Zoom Conference, said that government is yet to show interest in the drug calling on the National Assembly to organise emergency Public hearing on this issue.
He said the lawmakers, through their oversight function should direct agency concern to fast track the process of validating the drug.
Iwu said: “Government needs to show interest on our drug, the money raised by private sectors can be deployed, it does not need to come to Prof. Iwu, it is information, the product is ours, but the information is already outside.
“There must be interest on the part of government that they want to test the drug, once the government shows interest; every other thing will fall in place.”
Iwu said the lawmakers can have public hearing on the drug and ask why the validation for the drug is taking longer than necessary.